Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer

Du Geon Moon, Jun Cheon, Je-Jong Kim, Duck Ki Yoon, Sung Kun Koh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: We performed this study to assess the efficacy of prostate-specific antigen adjusted for the transition zone volume (PSATZ) and free-to-total prostate-specific antigen (PSA) ratio (F/T ratio) in predicting prostate cancer in men with intermediate PSA levels of 4.1-10.0 ng/mL. Methods: Between March 1997 and September 1998, PSATZ was obtained from 67 patients who underwent ultrasonography guided systemic sextant biopsies and had a PSA of 4.1-10.0 ng/mL. PSATZ was compared with F/T ratio via receiver operating characteristic (ROC) curves. Results: Of 67 patients, 22 (32.8%) had prostate cancer and 45 (67.2%) had benign prostatic hyperplasia (BPH) on pathologic examination. Mean PSA, PSA density, F/T ratio and PSATZ were 7.96 ± 2.01 ng/mL, 0.28 ± 0.14 ng/mL/cc, 0.10 ± 0.06 and 0.70 ± 0.28 ng/mL/cc in patients with prostate cancer and 6.39 ± 1.68 ng/mL, 0.16 ± 0.06 ng/mL/cc, 0.15 ± 0.05 and 0.29 ± 0.10 ng/mL/cc in patients with BPH, respectively. The ROC curve analysis demonstrated that PSATZ predicted the biopsy outcome significantly better than F/T ratio in all 67 patients (P < 0.01) and in a subset of 53 men with normal digital rectal examination (P < 0.01). With a cut-off value of 0.35 ng/mL/cc, PSATZ had a sensitivity of 86% and a specificity of 89% for predicting prostate cancer. Conclusions: These results suggest that PSATZ and F/T ratio may be useful in diagnosing prostate cancer with intermediate levels of PSA. Prostate-specific antigen adjusted for the transition zone volume is more accurate than F/T ratio in distinguishing benign prostatic disease from prostate cancer. But large prospective studies are required to assess the precise role of PSATZ and F/T ratio in early prostate cancer detection.

Original languageEnglish
Pages (from-to)455-462
Number of pages8
JournalInternational Journal of Urology
Volume6
Issue number9
DOIs
Publication statusPublished - 1999 Sep 20

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Prostatic Hyperplasia
ROC Curve
Prostatic Diseases
Biopsy
Digital Rectal Examination
Early Detection of Cancer
Ultrasonography

Keywords

  • Free-to-total prostate-specific antigen ratio
  • Prostate cancer
  • Prostate-specific antigen
  • Prostate-specific antigen adjusted for the transition zone volume

ASJC Scopus subject areas

  • Urology

Cite this

Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer. / Moon, Du Geon; Cheon, Jun; Kim, Je-Jong; Yoon, Duck Ki; Koh, Sung Kun.

In: International Journal of Urology, Vol. 6, No. 9, 20.09.1999, p. 455-462.

Research output: Contribution to journalArticle

@article{b1a834c4acb3444a91088ab7e9c1955e,
title = "Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer",
abstract = "Background: We performed this study to assess the efficacy of prostate-specific antigen adjusted for the transition zone volume (PSATZ) and free-to-total prostate-specific antigen (PSA) ratio (F/T ratio) in predicting prostate cancer in men with intermediate PSA levels of 4.1-10.0 ng/mL. Methods: Between March 1997 and September 1998, PSATZ was obtained from 67 patients who underwent ultrasonography guided systemic sextant biopsies and had a PSA of 4.1-10.0 ng/mL. PSATZ was compared with F/T ratio via receiver operating characteristic (ROC) curves. Results: Of 67 patients, 22 (32.8{\%}) had prostate cancer and 45 (67.2{\%}) had benign prostatic hyperplasia (BPH) on pathologic examination. Mean PSA, PSA density, F/T ratio and PSATZ were 7.96 ± 2.01 ng/mL, 0.28 ± 0.14 ng/mL/cc, 0.10 ± 0.06 and 0.70 ± 0.28 ng/mL/cc in patients with prostate cancer and 6.39 ± 1.68 ng/mL, 0.16 ± 0.06 ng/mL/cc, 0.15 ± 0.05 and 0.29 ± 0.10 ng/mL/cc in patients with BPH, respectively. The ROC curve analysis demonstrated that PSATZ predicted the biopsy outcome significantly better than F/T ratio in all 67 patients (P < 0.01) and in a subset of 53 men with normal digital rectal examination (P < 0.01). With a cut-off value of 0.35 ng/mL/cc, PSATZ had a sensitivity of 86{\%} and a specificity of 89{\%} for predicting prostate cancer. Conclusions: These results suggest that PSATZ and F/T ratio may be useful in diagnosing prostate cancer with intermediate levels of PSA. Prostate-specific antigen adjusted for the transition zone volume is more accurate than F/T ratio in distinguishing benign prostatic disease from prostate cancer. But large prospective studies are required to assess the precise role of PSATZ and F/T ratio in early prostate cancer detection.",
keywords = "Free-to-total prostate-specific antigen ratio, Prostate cancer, Prostate-specific antigen, Prostate-specific antigen adjusted for the transition zone volume",
author = "Moon, {Du Geon} and Jun Cheon and Je-Jong Kim and Yoon, {Duck Ki} and Koh, {Sung Kun}",
year = "1999",
month = "9",
day = "20",
doi = "10.1046/j.1442-2042.1999.00089.x",
language = "English",
volume = "6",
pages = "455--462",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer

AU - Moon, Du Geon

AU - Cheon, Jun

AU - Kim, Je-Jong

AU - Yoon, Duck Ki

AU - Koh, Sung Kun

PY - 1999/9/20

Y1 - 1999/9/20

N2 - Background: We performed this study to assess the efficacy of prostate-specific antigen adjusted for the transition zone volume (PSATZ) and free-to-total prostate-specific antigen (PSA) ratio (F/T ratio) in predicting prostate cancer in men with intermediate PSA levels of 4.1-10.0 ng/mL. Methods: Between March 1997 and September 1998, PSATZ was obtained from 67 patients who underwent ultrasonography guided systemic sextant biopsies and had a PSA of 4.1-10.0 ng/mL. PSATZ was compared with F/T ratio via receiver operating characteristic (ROC) curves. Results: Of 67 patients, 22 (32.8%) had prostate cancer and 45 (67.2%) had benign prostatic hyperplasia (BPH) on pathologic examination. Mean PSA, PSA density, F/T ratio and PSATZ were 7.96 ± 2.01 ng/mL, 0.28 ± 0.14 ng/mL/cc, 0.10 ± 0.06 and 0.70 ± 0.28 ng/mL/cc in patients with prostate cancer and 6.39 ± 1.68 ng/mL, 0.16 ± 0.06 ng/mL/cc, 0.15 ± 0.05 and 0.29 ± 0.10 ng/mL/cc in patients with BPH, respectively. The ROC curve analysis demonstrated that PSATZ predicted the biopsy outcome significantly better than F/T ratio in all 67 patients (P < 0.01) and in a subset of 53 men with normal digital rectal examination (P < 0.01). With a cut-off value of 0.35 ng/mL/cc, PSATZ had a sensitivity of 86% and a specificity of 89% for predicting prostate cancer. Conclusions: These results suggest that PSATZ and F/T ratio may be useful in diagnosing prostate cancer with intermediate levels of PSA. Prostate-specific antigen adjusted for the transition zone volume is more accurate than F/T ratio in distinguishing benign prostatic disease from prostate cancer. But large prospective studies are required to assess the precise role of PSATZ and F/T ratio in early prostate cancer detection.

AB - Background: We performed this study to assess the efficacy of prostate-specific antigen adjusted for the transition zone volume (PSATZ) and free-to-total prostate-specific antigen (PSA) ratio (F/T ratio) in predicting prostate cancer in men with intermediate PSA levels of 4.1-10.0 ng/mL. Methods: Between March 1997 and September 1998, PSATZ was obtained from 67 patients who underwent ultrasonography guided systemic sextant biopsies and had a PSA of 4.1-10.0 ng/mL. PSATZ was compared with F/T ratio via receiver operating characteristic (ROC) curves. Results: Of 67 patients, 22 (32.8%) had prostate cancer and 45 (67.2%) had benign prostatic hyperplasia (BPH) on pathologic examination. Mean PSA, PSA density, F/T ratio and PSATZ were 7.96 ± 2.01 ng/mL, 0.28 ± 0.14 ng/mL/cc, 0.10 ± 0.06 and 0.70 ± 0.28 ng/mL/cc in patients with prostate cancer and 6.39 ± 1.68 ng/mL, 0.16 ± 0.06 ng/mL/cc, 0.15 ± 0.05 and 0.29 ± 0.10 ng/mL/cc in patients with BPH, respectively. The ROC curve analysis demonstrated that PSATZ predicted the biopsy outcome significantly better than F/T ratio in all 67 patients (P < 0.01) and in a subset of 53 men with normal digital rectal examination (P < 0.01). With a cut-off value of 0.35 ng/mL/cc, PSATZ had a sensitivity of 86% and a specificity of 89% for predicting prostate cancer. Conclusions: These results suggest that PSATZ and F/T ratio may be useful in diagnosing prostate cancer with intermediate levels of PSA. Prostate-specific antigen adjusted for the transition zone volume is more accurate than F/T ratio in distinguishing benign prostatic disease from prostate cancer. But large prospective studies are required to assess the precise role of PSATZ and F/T ratio in early prostate cancer detection.

KW - Free-to-total prostate-specific antigen ratio

KW - Prostate cancer

KW - Prostate-specific antigen

KW - Prostate-specific antigen adjusted for the transition zone volume

UR - http://www.scopus.com/inward/record.url?scp=0032852450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032852450&partnerID=8YFLogxK

U2 - 10.1046/j.1442-2042.1999.00089.x

DO - 10.1046/j.1442-2042.1999.00089.x

M3 - Article

C2 - 10510891

AN - SCOPUS:0032852450

VL - 6

SP - 455

EP - 462

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 9

ER -